Cargando…
Management of Non-Colorectal Digestive Cancers with Microsatellite Instability
SIMPLE SUMMARY: Microsatellite instability (MSI) is an established predictive biomarker for immune checkpoint inhibitors with potential prognostic value in different types of tumors. Its prevalence and clinical utility vary in gastrointestinal cancers. In this review, we will discuss the role of MSI...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915546/ https://www.ncbi.nlm.nih.gov/pubmed/33561950 http://dx.doi.org/10.3390/cancers13040651 |
_version_ | 1783657268359725056 |
---|---|
author | Zhu, Mojun Jin, Zhaohui Hubbard, Joleen M. |
author_facet | Zhu, Mojun Jin, Zhaohui Hubbard, Joleen M. |
author_sort | Zhu, Mojun |
collection | PubMed |
description | SIMPLE SUMMARY: Microsatellite instability (MSI) is an established predictive biomarker for immune checkpoint inhibitors with potential prognostic value in different types of tumors. Its prevalence and clinical utility vary in gastrointestinal cancers. In this review, we will discuss the role of MSI status in the management of non-colorectal cancers of the digestive system and address ongoing research work and mechanistic rationale(s) for future studies in this field. ABSTRACT: Microsatellite instability (MSI) is a hallmark of genetic predisposition to DNA damage. It arises from either germline or somatic events leading to impaired function of the mismatch repair system. It can be detected via genetic sequencing or immunohistochemistry with relatively high concordance rates. The presence of MSI in a tumor reflects a high neoantigen load and predicts favorable treatment response to immune checkpoint inhibitors (ICIs). In gastrointestinal cancers, MSI is a predictive biomarker for ICIs with potential prognostic impact but its clinical utility varies widely depending on tumor type. This may be explained by the complexity of tumor microenvironment as highlighted by recent translational studies. In this review, we will discuss the predictive and prognostic value of MSI status in non-colorectal cancers of the digestive system, important clinical trials involving ICIs and potential strategies to overcome resistance to immunotherapy. |
format | Online Article Text |
id | pubmed-7915546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79155462021-03-01 Management of Non-Colorectal Digestive Cancers with Microsatellite Instability Zhu, Mojun Jin, Zhaohui Hubbard, Joleen M. Cancers (Basel) Review SIMPLE SUMMARY: Microsatellite instability (MSI) is an established predictive biomarker for immune checkpoint inhibitors with potential prognostic value in different types of tumors. Its prevalence and clinical utility vary in gastrointestinal cancers. In this review, we will discuss the role of MSI status in the management of non-colorectal cancers of the digestive system and address ongoing research work and mechanistic rationale(s) for future studies in this field. ABSTRACT: Microsatellite instability (MSI) is a hallmark of genetic predisposition to DNA damage. It arises from either germline or somatic events leading to impaired function of the mismatch repair system. It can be detected via genetic sequencing or immunohistochemistry with relatively high concordance rates. The presence of MSI in a tumor reflects a high neoantigen load and predicts favorable treatment response to immune checkpoint inhibitors (ICIs). In gastrointestinal cancers, MSI is a predictive biomarker for ICIs with potential prognostic impact but its clinical utility varies widely depending on tumor type. This may be explained by the complexity of tumor microenvironment as highlighted by recent translational studies. In this review, we will discuss the predictive and prognostic value of MSI status in non-colorectal cancers of the digestive system, important clinical trials involving ICIs and potential strategies to overcome resistance to immunotherapy. MDPI 2021-02-06 /pmc/articles/PMC7915546/ /pubmed/33561950 http://dx.doi.org/10.3390/cancers13040651 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhu, Mojun Jin, Zhaohui Hubbard, Joleen M. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability |
title | Management of Non-Colorectal Digestive Cancers with Microsatellite Instability |
title_full | Management of Non-Colorectal Digestive Cancers with Microsatellite Instability |
title_fullStr | Management of Non-Colorectal Digestive Cancers with Microsatellite Instability |
title_full_unstemmed | Management of Non-Colorectal Digestive Cancers with Microsatellite Instability |
title_short | Management of Non-Colorectal Digestive Cancers with Microsatellite Instability |
title_sort | management of non-colorectal digestive cancers with microsatellite instability |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915546/ https://www.ncbi.nlm.nih.gov/pubmed/33561950 http://dx.doi.org/10.3390/cancers13040651 |
work_keys_str_mv | AT zhumojun managementofnoncolorectaldigestivecancerswithmicrosatelliteinstability AT jinzhaohui managementofnoncolorectaldigestivecancerswithmicrosatelliteinstability AT hubbardjoleenm managementofnoncolorectaldigestivecancerswithmicrosatelliteinstability |